Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Magnolol
Cat. No.:
OB0225LY-0404
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
Magnolol is a dual agonist of RXRα and PPARγ.
Synonym:
NSC 293099; 5,5'-Diallyl-2,2'-biphenyldiol; 528-43-8; 5,5'-Diallyl-[1,1'-biphenyl]-2,2'-diol; 2,2'-Bichavicol; 2-(2-Hydroxy-5-prop-2-enylphenyl)-4-prop-2-enylphenol; 4-Allyl-2-(5-allyl-2-hydroxy-phenyl)phenol; 5,5'-Bis(prop-2-en-1-yl)-[1,1'-biphenyl]-2,2'-diol
CAS No.:
528-43-8
Compound CID:
72300
Formula:
C18H18O2
Formula Weight:
266.33
Specification
Relative Density:
1.107 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Magnolol can be used to block TNF-α-induced NF-KB activation.
Library Information
Targets:
PPAR; Retinoid receptor; p53; NF-κB
Receptors:
PPARγ; RAR/RXR; RXRα
Pathways:
Metabolism; Autophagy; Microbiology/Virology; Apoptosis; DNA damage/DNA repair; NF-κB
Plate Number:
AOCL-6
Plate Location:
b10
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
70 mg/mL; 262.83 mM
Water Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
Ethanol Max Solubility:
49 mg/mL; 184 mM
ALogP:
4.88
HBA_Count:
0
HBD_Count:
2
Rotatable Bond:
5
